Sanford Auerbach is a Neurology physician affiliated with Boston University. OpenAlex indexes 140 publications with 9,329 citations (h-index 43).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street, Suite 7b
Shapiro Bldg
Boston, MA 02118
Telephone
617-638-8456Provider last certified this registry record 2 Mar 2026.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ZOLL Respicardia, Inc.Program year20242 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20241 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%SSRI26.8%Sertraline Hcl62%Escitalopram Oxalate23%Trazodone Hcl15%Part D<11 patientsCholinesterase Inhibitor16.9%Donepezil Hcl100%Part D≥11 patients+ 9 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1999–2004 per NIH RePORTER. The latest:
- Acute Effects of Lecithin in Early Alzheimer's Disease
Boston University Medical Campus
FY2004$5,786M01RR000533 - ACTG 301, TRIAL OF MEMANTINE FOR ADC AS TREATMENT W/ ANTIRETROVIRAL THERAPY
Boston University Medical Campus
FY2001M01RR000533 - ACTG 301, TRIAL OF MEMANTINE FOR ADC AS TREATMENT W/ ANTIRETROVIRAL THERAPY
Boston University Medical Campus
FY2000$30,487M01RR000533
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Is dietary choline intake related to dementia and Alzheimer’s disease risks? Results from the Framingham Heart Study
American Journal of Clinical Nutrition
2022 - Mid- to Late-Life Body Mass Index and Dementia Risk: 38 Years of Follow-up of the Framingham Study
American Journal of Epidemiology
2021 - Association Between the Digital Clock Drawing Test and Neuropsychological Test Performance: Large Community-Based Prospective Cohort (Framingham Heart Study)
Journal of Medical Internet Research
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
Joseph Antin, MD
Boston University
George O'Connor, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”